What is he best known for?
The fields of study he is best known for:
His main research concerns Genetics, Cancer research, Gene, Cancer and Exome.
His Cancer research study combines topics from a wide range of disciplines, such as DNA methylation, Bioinformatics, Transcriptome, CDKN2A and PTEN.
His work carried out in the field of DNA methylation brings together such families of science as 1p/19q Codeletion, Serous fluid, Microsatellite instability, KRAS and microRNA.
He has researched Gene in several fields, including Melanoma and Adenocarcinoma.
Michael S. Lawrence has included themes like Exome sequencing, Fusion gene, Immunology and Chronic lymphocytic leukemia in his Cancer study.
His Exome study incorporates themes from Glioma, Pathology, Breast cancer, Mutation rate and Genetic heterogeneity.
His most cited work include:
- Comprehensive molecular portraits of human breast tumours (7253 citations)
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (5484 citations)
- Comprehensive molecular characterization of human colon and rectal cancer (5012 citations)
What are the main themes of his work throughout his whole career to date?
Michael S. Lawrence spends much of his time researching Genetics, Cancer research, Gene, Cancer and Mutation.
His studies in Genome, Exome, Exome sequencing, Germline mutation and Somatic cell are all subfields of Genetics research.
His biological study spans a wide range of topics, including Genetic heterogeneity and Adenocarcinoma.
His Cancer research study also includes fields such as
- DNA methylation, which have a strong connection to microRNA,
- Cancer cell and related Signal transduction.
His study looks at the relationship between Gene and fields such as Computational biology, as well as how they intersect with chemical problems.
His Cancer study is concerned with the larger field of Internal medicine.
He most often published in these fields:
- Genetics (42.95%)
- Cancer research (37.62%)
- Gene (31.35%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (37.62%)
- Computational biology (15.67%)
- Gene (31.35%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Computational biology, Gene, Cancer and Genome.
The Cancer research study combines topics in areas such as Cell, DNA damage, Cancer cell, Carcinogenesis and Lung cancer.
His studies in Computational biology integrate themes in fields like Mutagenesis, DNA methylation, APOBEC3A, Cluster analysis and Genomics.
Gene connects with themes related to Oxidative phosphorylation in his study.
His Genome study improves the overall literature in Genetics.
Michael S. Lawrence connects Genetics with Gene nomenclature in his research.
Between 2017 and 2021, his most popular works were:
- Comprehensive Characterization of Cancer Driver Genes and Mutations (867 citations)
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. (707 citations)
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. (707 citations)
In his most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Computational biology, Cancer research, Genome, Gene and Lung cancer.
His Computational biology research is multidisciplinary, relying on both International Prognostic Index, DNA methylation, Mutation, Genomics and DNA replication.
His Cancer research study combines topics in areas such as Cancer, Oncogene, microRNA and Transcription factor.
His Genome research integrates issues from Chromothripsis, Germline mutation, Aneuploidy and Point mutation.
Aneuploidy is a subfield of Genetics that Michael S. Lawrence explores.
Carcinogenesis and Missense mutation are among the areas of Gene where the researcher is concentrating his efforts.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
